<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252716</url>
  </required_header>
  <id_info>
    <org_study_id>Visth 1.5 BER-401-19</org_study_id>
    <nct_id>NCT04252716</nct_id>
  </id_info>
  <brief_title>VISPER: Randomised Comparison of Two OVDs in Cataract Surgery</brief_title>
  <acronym>VISPER</acronym>
  <official_title>Prospective, Randomized, Multi-centre, Observer-masked, Non-inferiority Comparison of Two Cohesive Viscoelastic Solutions: VISTHESIA v Provisc</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate that VISTHESIA 1.5 is non-inferior to Provisc with regards to elevation in IOP&#xD;
      greater than or equal to 30 mm Hg 6 ± 2 hours post-operatively as per methodology set out in&#xD;
      EN ISO 15798:2013 (Primary Endpoint) To compare the changes in endothelial cell count and&#xD;
      incidences of intraocular inflammation between VISTHESIA and Provisc as per methodology set&#xD;
      out in EN ISO 15798:2013&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IOP</measure>
    <time_frame>6-hours post-operatively</time_frame>
    <description>Frequency of incidence of Intraocular Pressure greater than or equal to 30 mm Hg</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>VISTHESIA 1.5</arm_group_label>
    <description>Ophtalmologic surgery supported by Visthesia OVD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ProVisc</arm_group_label>
    <description>Ophtalmologic surgery supported by Provisc OVD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OVD</intervention_name>
    <description>Intraocular administration</description>
    <arm_group_label>ProVisc</arm_group_label>
    <arm_group_label>VISTHESIA 1.5</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in need of cataract surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of any gender, 50 years of age or older at the time of study enrolment&#xD;
&#xD;
          2. undergoing age-related cataract removal (phacoemulsification) and IOL implantation in&#xD;
             one eye only&#xD;
&#xD;
          3. Patient informed of the needs and visit schedule required of the Clinical&#xD;
             Investigational Plan and who has given his/her written informed consent&#xD;
&#xD;
          4. Planned implantation of the IOL in the capsular bag&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients not able to / willing to give informed consent&#xD;
&#xD;
          2. Patients not able to comprehend and comply with study requirements&#xD;
&#xD;
          3. Patients scheduled for surgery to the fellow eye within 48 hrs preceding any scheduled&#xD;
             study follow up. (Surgery date could be changed)&#xD;
&#xD;
          4. Patients not able to attend follow-up appointments for any reason&#xD;
&#xD;
          5. Patients with known hypersensitivity to anaesthetics of the amide type or hyaluronan&#xD;
&#xD;
          6. Patients with reduced corneal endothelium (e.g. Fuch's dystrophy)&#xD;
&#xD;
          7. Patients with epilepsy, impaired cardiac conduction, bradycardia, or impaired&#xD;
             respiratory function&#xD;
&#xD;
          8. Patients being treated with tocainide for cardiac arrhythmia&#xD;
&#xD;
          9. Patients with impaired hepatic function, if the anaesthetic dose or site of&#xD;
             application is likely to result in high blood levels&#xD;
&#xD;
         10. Mono-ophthalmic patients&#xD;
&#xD;
         11. Patients who have previously undergone cataract surgery in the contralateral eye&#xD;
&#xD;
         12. Patients with any psychosocial, or other chronic disease conditions that may affect&#xD;
             the perception of bodily pain&#xD;
&#xD;
         13. VISTHESIA (topical and intracameral components) or ProVisc is not a suitable device&#xD;
             for the patient for any reason&#xD;
&#xD;
         14. Patients with other pathology or condition presenting, according to the investigator&#xD;
             opinion, a risk for the patient (to be documented in screen log)&#xD;
&#xD;
         15. Female patients who are menstruating, pregnant, breastfeeding or amenorrheic for less&#xD;
             than 2 years at the time of surgery&#xD;
&#xD;
         16. Patients who may require the use of hyaluronidase as part of the study cataract&#xD;
             procedure&#xD;
&#xD;
         17. Patients who may be regarded as being vulnerable (e.g. prisoners, residents of care or&#xD;
             mental health institutions, trauma, war or disaster victims, dependent on the&#xD;
             investigator etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Doris Wolf</last_name>
    <phone>+4930854001383</phone>
    <email>doris.wolf@zeiss.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Boehringer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

